Skip to main content
Michael Pishvaian, MD, Oncology, Washington, DC

MichaelJonPishvaianMDPhD

Oncology Washington, DC

Gastrointestinal Cancer

Associate Professor, Johns Hopkins University School of Medicine

Dr. Pishvaian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Pishvaian's full profile

Already have an account?

  • Office

    5255 Loughboro Road Northwest
    Washington, DC 20016
    Phone+1 202-660-6500
    Fax+1 202-660-6501

Education & Training

  • MedStar Health/Georgetown University Hospital
    MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2004 - 2007
  • MedStar Health/Georgetown University Hospital
    MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2001 - 2004
  • Georgetown University
    Georgetown UniversityPh.D., Cell Biology/Tumor Biology, 1993 - 2001
  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 2001
  • Duke University
    Duke UniversityBS, Biology, Cum Laude, 1989 - 1993

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2010 - 2025
  • DC State Medical License
    DC State Medical License 2004 - 2024
  • TX State Medical License
    TX State Medical License 2019 - 2021
  • VA State Medical License
    VA State Medical License 2001 - 2010
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • First Place Award Winner Department of Internal Medicine �Research Day�, 2007
  • Honors Certificate in Cell and Molecular Biology 1993
  • Dean�s List 1990

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer  
    Pishvaian MJ, Garrido-Laguna I, Liu SV, Multani PS, Chow-Maneval E, Rolfo C., JCO Precision Oncology, 1/1/2018
  • Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer  
    John Marshall, Sean Collins, Keith Unger, Aidan Burke, Marie Gurka, Michael Pishvaian, Journal of Gastrointestinal Cancer
  • Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine  
    Harris M, Bhuvaneshwar K, Natarajan T, Sheahan L, Wang D, Tadesse MG, Shoulson I, Filice R, Steadman K, Pishvaian MJ, Madhavan S, Deeken J., Pharmacogenet Genomics, 1/1/2014
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesop...
    Michael Cerniglia, Joanne Xiu, Axel Grothey, Michael J. Pishvaian, Jimmy J. Hwang, John Marshall, Ari M. Vanderwalde, Anthony Frank Shields, Heinz-Josef Lenz, Mohamed ..., Gastrointestinal Cancers Symposium, J Clin Oncol, 1/1/2019
  • Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program
    Michael J. Pishvaian, Edik Matthew Blais, Jonathan Robert Brody, Davendra Sohal, Andrew Eugene Hendifar, Vincent Chung, Sameh Mikhail, Lola Rahib, Emily Lyons, Lisa Ti..., Gastrointestinal Cancers Symposium, J Clin Oncol, 1/1/2019
  • A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.
    Benjamin Adam Weinberg, Hongkun Wang, Agnieszka Katarzyna Witkiewicz, John Marshall, Erik S. Knudsen, Michael J. Pishvaian., J Clin Oncol, 1/1/2018
  • Join now to see all

Lectures

  • Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionab... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC). 
    2019 ASCO Annual Meeting - 6/1/2019
  • Precision Medicine in GI Cancers: Targeting the DNA Damage Repair Pathway 
    MD Anderson Cancer Center - 1/1/2018
  • Join now to see all

Other

  • Precision Medicine for Pancreatic Cancer 
    Pancreatic Cancer Action Network Webinar
    Washington, DC - 1/1/2017
  • Epidermal Growth Factor Inhibitors 
    Pishvaian M, Wang D, He R, Marshall JL, Encyclopedia of Cancer
    1/1/2009
  • Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents 
    Pishvaian, MJ and Wellstein, A, Cancernetwork.com
    1/1/2008

Press Mentions

  • Targeted Therapy May Increase Overall Survival in Patients with Pancreatic Cancer
    Targeted Therapy May Increase Overall Survival in Patients with Pancreatic CancerMarch 3rd, 2020
  • Platinum-Based Therapy Can Significantly Improve Survival for Some Pancreatic Cancer Patients
    Platinum-Based Therapy Can Significantly Improve Survival for Some Pancreatic Cancer PatientsAugust 27th, 2019
  • Supreme Court: Ginsburg Treated for Tumor on Pancreas
    Supreme Court: Ginsburg Treated for Tumor on PancreasAugust 23rd, 2019
  • Join now to see all

Professional Memberships